Denys Damiaan
Department of Anxiety Disorders, Rudolf Magnus Institute of Neuroscience, Utrecht, The Netherlands.
Psychiatr Clin North Am. 2006 Jun;29(2):553-84, xi. doi: 10.1016/j.psc.2006.02.013.
This article reviews new developments of pharmacotherapy in obsessive-compulsive disorder (OCD) and OC spectrum disorders of the past five years. New developments primarily involved the ex-tension of evidence of efficacy of serotonin reuptake inhibitors(SRIs), the use of atypical antipsychotics in addition to SRIs for treatment refractory patients, the combination of pharmacotherapy with behavior therapy, and studies assessing predictors of response. Today, frontline pharmacological treatment of OCD still consists of drugs with potent serotonin reuptake inhibition proper-ties. In case of non-response, treatment options comprise adding another drug, increasing the dose, switching drugs, or changing the mode of delivery.
本文回顾了过去五年强迫症（OCD）及强迫症谱系障碍药物治疗的新进展。新进展主要包括5-羟色胺再摄取抑制剂（SRIs）疗效证据的扩展、对难治性患者在使用SRIs基础上加用非典型抗精神病药物、药物治疗与行为疗法的联合应用以及评估反应预测因素的研究。如今，强迫症的一线药物治疗仍由具有强效5-羟色胺再摄取抑制特性的药物组成。若治疗无反应，治疗选择包括加用另一种药物、增加剂量、更换药物或改变给药方式。
